Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8417)
All Articles published online
|
Publishing Process of This Article
|
Jul 14, 2014 (publication date) through Jun 17, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Nordh S, Ansari D, Andersson R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review. World J Gastroenterol 2014; 20(26): 8482-8490 [PMID: 25024604 DOI: 10.3748/wjg.v20.i26.8482] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i26/8482.htm |
| Number | Citing Articles |
| 1 |
Matthew J. Reilley, Gauri R. Varadhachary. Multimodality Management of Borderline Resectable Pancreatic Cancer. 2016; : 91 doi: 10.1007/978-3-319-22780-1_6
|
| 2 |
Stephanie E. Combs. Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors. Langenbeck's Archives of Surgery 2015; 400(7): 749 doi: 10.1007/s00423-015-1309-8
|
| 3 |
Lee Cheng Phua, Shixu Goh, David Wai Meng Tai, Wei Qiang Leow, Syed Muhammad Fahmy Alkaff, Chung Yip Chan, Juinn Huar Kam, Tony Kiat Hon Lim, Eric Chun Yong Chan. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. Cancer Chemotherapy and Pharmacology 2018; 81(2): 277 doi: 10.1007/s00280-017-3475-6
|
| 4 |
Kombo F. N’Guessan, Harold W. Davis, Zhengtao Chu, Subrahmanya D. Vallabhapurapu, Clayton S. Lewis, Robert S. Franco, Olugbenga Olowokure, Syed A. Ahmad, Jen Jen Yeh, Vladimir Y. Bogdanov, Xiaoyang Qi. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer. Molecular Therapy 2020; 28(8): 1876 doi: 10.1016/j.ymthe.2020.05.013
|
| 5 |
Qiqing Sun, Wenyan Xu, Shunrong Ji, Yi Qin, Wensheng Liu, Qiangsheng Hu, Zheng Zhang, Mengqi Liu, Xianjun Yu, Xiaowu Xu. Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Cancer Cell International 2019; 19(1) doi: 10.1186/s12935-019-0767-4
|
| 6 |
Neal Bhutiani, Steven Agle, Yan Li, Suping Li, Robert C.G. Martin. Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma. Journal of Surgical Oncology 2016; 114(2): 181 doi: 10.1002/jso.24288
|
| 7 |
Mansi Arora, James M. Bogenberger, Amro Abdelrahman, Jennifer L. Leiting, Xianfeng Chen, Jan B. Egan, Aradhana Kasimsetty, Elzbieta Lenkiewicz, Smriti Malasi, Pedro Luiz Serrano Uson, Bolni Marius Nagalo, Yumei Zhou, Marcela A. Salomao, Heidi E. Kosiorek, Esteban Braggio, Michael T. Barrett, Mark J. Truty, Mitesh J. Borad. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer Chemotherapy and Pharmacology 2020; 85(6): 1063 doi: 10.1007/s00280-020-04079-z
|
| 8 |
Hong-wei Yang, Guang-hui Liu, Yu-qiong Liu, Hong-chao Zhao, Zhen Yang, Chun-lin Zhao, Xie-fu Zhang, Hua Ye. Over-expression of microRNA-940 promotes cell proliferation by targeting GSK3β and sFRP1 in human pancreatic carcinoma. Biomedicine & Pharmacotherapy 2016; 83: 593 doi: 10.1016/j.biopha.2016.06.057
|
| 9 |
S.-J. Cui, T.-Y. Tang, X.-W. Zou, Q.-M. Su, L. Feng, X.-Y. Gong. Role of imaging biomarkers for prognostic prediction in patients with pancreatic ductal adenocarcinoma. Clinical Radiology 2020; 75(6): 478.e1 doi: 10.1016/j.crad.2019.12.023
|
| 10 |
Kumiko Ueda, Ayasa Masuda, Misaki Fukuda, Shota Tanaka, Mika Hosokawa, Seigo Iwakawa. Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells. Drug Metabolism and Pharmacokinetics 2017; 32(6): 301 doi: 10.1016/j.dmpk.2017.10.001
|
| 11 |
Justine M. Grixti, Steve O'Hagan, Philip J. Day, Douglas B. Kell. Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. Frontiers in Pharmacology 2017; 8 doi: 10.3389/fphar.2017.00155
|
| 12 |
Joseph Ciccolini, Cindy Serdjebi, Hau Le Thi Thu, Bruno Lacarelle, Gerard Milano, Raphaelle Fanciullino. Nucleoside analogs: ready to enter the era of precision medicine?. Expert Opinion on Drug Metabolism & Toxicology 2016; 12(8): 865 doi: 10.1080/17425255.2016.1192128
|
| 13 |
Douglas B. Kell, Stephen G. Oliver. How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Frontiers in Pharmacology 2014; 5 doi: 10.3389/fphar.2014.00231
|
| 14 |
Marek Sierzega, Radosław Pach, Piotr Kulig, Janusz Legutko, Jan Kulig. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy. Pancreas 2017; 46(5): 684 doi: 10.1097/MPA.0000000000000807
|
| 15 |
Larissa J. Vos, Dimas Yusuf, Arthur Lui, Zainab Abdelaziz, Sunita Ghosh, Jennifer L. Spratlin, John R. Mackey. Predictive and Prognostic Properties of Human Equilibrative Nucleoside Transporter 1 Expression in Gemcitabine-Treated Pancreatobiliary Cancer: A Meta-Analysis. JCO Precision Oncology 2019; (3): 1 doi: 10.1200/PO.18.00240
|
| 16 |
Hiroyuki Saito, Hiroshi Kashiyama, Takashi Murohashi, Kazunari Sasaki, Ryosuke Misawa, Susumu Ohwada. Case of Six-Year Disease-Free Survival with Undifferentiated Carcinoma of the Pancreas. Case Reports in Gastroenterology 2016; 10(2): 472 doi: 10.1159/000448878
|
| 17 |
Simona Mura, Elias Fattal, Julien Nicolas. From poly(alkyl cyanoacrylate) to squalene as core material for the design of nanomedicines. Journal of Drug Targeting 2019; 27(5-6): 470 doi: 10.1080/1061186X.2019.1579822
|
| 18 |
Lucie Jiraskova, Ales Ryska, Erik Jurjen Duintjer Tebbens, Helena Hornychova, Filip Cecka, Frantisek Staud, Lukas Cerveny. Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?. Cancers 2019; 11(11): 1621 doi: 10.3390/cancers11111621
|
| 19 |
Radim Moravec, Rao Divi, Mukesh Verma. Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World Journal of Gastrointestinal Oncology 2017; 9(6): 235-250 doi: 10.4251/wjgo.v9.i6.235
|
| 20 |
Weiyun Huang, Xin Zeng, Yigong Shi, Minhao Liu. Functional characterization of human equilibrative nucleoside transporter 1. Protein & Cell 2017; 8(4): 284 doi: 10.1007/s13238-016-0350-x
|
| 21 |
Girijesh Kumar Patel, Mohammad Aslam Khan, Arun Bhardwaj, Sanjeev K Srivastava, Haseeb Zubair, Mary C Patton, Seema Singh, Moh'd Khushman, Ajay P Singh. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. British Journal of Cancer 2017; 116(5): 609 doi: 10.1038/bjc.2017.18
|
| 22 |
Ornella Randazzo, Filippo Papini, Giulia Mantini, Alessandro Gregori, Barbara Parrino, Daniel S. K. Liu, Stella Cascioferro, Daniela Carbone, Godefridus J. Peters, Adam E. Frampton, Ingrid Garajova, Elisa Giovannetti. “Open Sesame?”: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer. Cancers 2020; 12(11): 3206 doi: 10.3390/cancers12113206
|
| 23 |
Rina Fujiwara-Tani, Takamitsu Sasaki, Tadataka Takagi, Shiori Mori, Shingo Kishi, Yukiko Nishiguchi, Hitoshi Ohmori, Kiyomu Fujii, Hiroki Kuniyasu. Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism. International Journal of Molecular Sciences 2022; 23(14): 7824 doi: 10.3390/ijms23147824
|
| 24 |
Yue Yu, Fei Ding, Meng Gao, Yi Jia, Le Ren. Establishment and characterization of the gemcitabine‑resistant human pancreatic cancer cell line SW1990/gemcitabine. Oncology Letters 2019; doi: 10.3892/ol.2019.10627
|
| 25 |
Mitsuru Okuno, Seiji Adachi, Osamu Kozawa, Masahito Shimizu, Ichiro Yasuda. The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic Cancer. International Journal of Molecular Sciences 2016; 17(1): 137 doi: 10.3390/ijms17010137
|
| 26 |
Toshinori Ozaki, Meng Yu, Danjing Yin, Dan Sun, Yuyan Zhu, Youquan Bu, Meixiang Sang. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-4217-9
|
| 27 |
Ali Belkouz, Tim A. Labeur, Joeri Dierks, Frederike Dijk, Martijn G.H. van Oijen, Joanne Verheij, Thomas M. van Gulik, Marc J. van de Vijver, Hanneke Wilmink, Cornelis J.A. Punt, Heinz-Josef Klümpen. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 2019; 141: 82 doi: 10.1016/j.critrevonc.2019.06.001
|
| 28 |
Eugene J. Koay, Matthew H.G. Katz, Huamin Wang, Xuemei Wang, Laura Prakash, Milind Javle, Rachna Shroff, David Fogelman, Santiago Avila, Mohamed Zaid, Dalia Elganainy, Yeonju Lee, Christopher H. Crane, Sunil Krishnan, Prajnan Das, Jason B. Fleming, Jeffrey E. Lee, Eric P. Tamm, Priya Bhosale, Jeffrey H. Lee, Brian Weston, Anirban Maitra, Robert A. Wolff, Gauri R. Varadhachary. Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precision Oncology 2019; (3): 1 doi: 10.1200/PO.19.00001
|
| 29 |
Qiangsheng Hu, Yi Qin, Bo Zhang, Chen Liang, Shunrong Ji, Si Shi, Wenyan Xu, Jinfeng Xiang, Dingkong Liang, Quanxing Ni, Xianjun Yu, Jin Xu. FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. Oncology Reports 2017; 38(4): 2069 doi: 10.3892/or.2017.5856
|
| 30 |
Jaya Aseervatham, Lucky Tran, Khaled Machaca, Olga Boudker, Hernâni Gerós. The Role of Flexible Loops in Folding, Trafficking and Activity of Equilibrative Nucleoside Transporters. PLOS ONE 2015; 10(9): e0136779 doi: 10.1371/journal.pone.0136779
|
| 31 |
Andrii Khomiak, Marius Brunner, Maximilian Kordes, Stina Lindblad, Rainer Christoph Miksch, Daniel Öhlund, Ivonne Regel. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Cancers 2020; 12(11): 3234 doi: 10.3390/cancers12113234
|
| 32 |
Balázs Vaskó, Viktória Juhász, Beáta Tóth, Anita Kurunczi, Zsolt Fekete, Joseph Krisjanis Zolnerciks, Emese Kis, Rémi Magnan, Axel Bidon-Chanal Badia, Marçal Pastor-Anglada, Eszter Hazai, Zsolt Bikadi, Ferenc Fülöp, Peter Krajcsi. Inhibitor selectivity of CNTs and ENTs. Xenobiotica 2019; 49(7): 840 doi: 10.1080/00498254.2018.1501832
|
| 33 |
Dunja Sobot, Simona Mura, Patrick Couvreur. How can nanomedicines overcome cellular-based anticancer drug resistance?. Journal of Materials Chemistry B 2016; 4(30): 5078 doi: 10.1039/C6TB00900J
|
| 34 |
Cristiana Correia, Cristina P. R. Xavier, Diana Duarte, Abigail Ferreira, Sara Moreira, M. Helena Vasconcelos, Nuno Vale. Development of potent CPP6–gemcitabine conjugates against human prostate cancer cell line (PC-3). RSC Medicinal Chemistry 2020; 11(2): 268 doi: 10.1039/C9MD00489K
|
| 35 |
René J. Boosman, Marie-Rose B. S. Crombag, Nielka P. van Erp, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema. Is age just a number? A population pharmacokinetic study of gemcitabine. Cancer Chemotherapy and Pharmacology 2022; 89(5): 697 doi: 10.1007/s00280-022-04431-5
|
| 36 |
Jakob Kirkegård, Morten Ladekarl, Ida Ravnsbæk Johannsen, Frank Mortensen. Effect of adjuvant chemotherapy after pancreatectomy in patients with node-negative pancreatic cancer: target trial emulation. British Journal of Surgery 2024; 111(1) doi: 10.1093/bjs/znad398
|
| 37 |
Daniel R. Principe, Patrick W. Underwood, Murray Korc, Jose G. Trevino, Hidayatullah G. Munshi, Ajay Rana. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.688377
|
| 38 |
Dunja Sobot, Simona Mura, Semen O. Yesylevskyy, Laura Dalbin, Fanny Cayre, Guillaume Bort, Julie Mougin, Didier Desmaële, Sinda Lepetre-Mouelhi, Grégory Pieters, Bohdan Andreiuk, Andrey S. Klymchenko, Jean-Louis Paul, Christophe Ramseyer, Patrick Couvreur. Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery. Nature Communications 2017; 8(1) doi: 10.1038/ncomms15678
|
| 39 |
Emmanouil Fokas, Eric O'Neill, Alex Gordon-Weeks, Somnath Mukherjee, W. Gillies McKenna, Ruth J. Muschel. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2015; 1855(1): 61 doi: 10.1016/j.bbcan.2014.12.001
|
| 40 |
M. Sinn, H. Riess, B.V. Sinn, J.M. Stieler, U. Pelzer, J.K. Striefler, H. Oettle, M. Bahra, C. Denkert, H. Bläker, P. Lohneis. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine – Results from the CONKO-001 trial. European Journal of Cancer 2015; 51(12): 1546 doi: 10.1016/j.ejca.2015.05.005
|
| 41 |
Wei Wang, Xinzhe Yu, Hengchao Li, Chuanxin Yang, Chen Jin, Xinyu Huang. hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02666-x
|
| 42 |
Sharon D. Stoker, Zlata Novalić, Maarten A. Wildeman, Alwin D. R. Huitema, Sandra A. W. M. Verkuijlen, Hedy Juwana, Astrid E. Greijer, I. Bing Tan, Jaap M. Middeldorp, Jan Paul de Boer. Epstein–Barr virus-targeted therapy in nasopharyngeal carcinoma. Journal of Cancer Research and Clinical Oncology 2015; 141(10): 1845 doi: 10.1007/s00432-015-1969-3
|
| 43 |
Christopher J. Endres, Aaron M. Moss, Kazuya Ishida, Rajgopal Govindarajan, Jashvant D. Unadkat. The role of the equilibrative nucleoside transporter 1 on tissue and fetal distribution of ribavirin in the mouse. Biopharmaceutics & Drug Disposition 2016; 37(6): 336 doi: 10.1002/bdd.2015
|
| 44 |
Ruud H. Wijdeven, Baoxu Pang, Yehuda G. Assaraf, Jacques Neefjes. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. Drug Resistance Updates 2016; 28: 65 doi: 10.1016/j.drup.2016.07.001
|
| 45 |
Kanwal Baloch, Liqiong Chen, Ameer A Memon, Laura Dexter, William Irving, Mohammad Ilyas, Brian J Thomson. Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin. Antiviral Chemistry and Chemotherapy 2017; 25(1): 2 doi: 10.1177/2040206616686894
|
| 46 |
Tomas Koltai, Stephan Joel Reshkin, Tiago M. A. Carvalho, Daria Di Molfetta, Maria Raffaella Greco, Khalid Omer Alfarouk, Rosa Angela Cardone. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers 2022; 14(10): 2486 doi: 10.3390/cancers14102486
|
| 47 |
Akanksha Patel, Aishwarya Saraswat, Harsh Patel, Zhe-Sheng Chen, Ketan Patel. Palmitoyl Carnitine-Anchored Nanoliposomes for Neovasculature-Specific Delivery of Gemcitabine Elaidate to Treat Pancreatic Cancer. Cancers 2022; 15(1): 182 doi: 10.3390/cancers15010182
|
| 48 |
Marie Sahlin, Monika Posaric Bauden, Roland Andersson, Daniel Ansari. Radioimmunotherapy—a potential novel tool for pancreatic cancer therapy?. Tumor Biology 2015; 36(6): 4053 doi: 10.1007/s13277-015-3479-y
|
| 49 |
Ashwaq H.S. Yehya, Muhammad Asif, Amin M.S. Abdul Majid, Chern E. Oon. Complementary effects of Orthosiphon stamineus standardized ethanolic extract and rosmarinic acid in combination with gemcitabine on pancreatic cancer. Biomedical Journal 2021; 44(6): 694 doi: 10.1016/j.bj.2020.05.015
|
| 50 |
Chemoresistance in Pancreatic Cancer. International Journal of Molecular Sciences 2019; 20(18): 4504 doi: 10.3390/ijms20184504
|
| 51 |
Ernest Osei, Christabel Oghinan, Akua Asare, Hillary Ho, Solomon Manful. Review of clinical and emerging biomarkers for early diagnosis and treatment management of pancreatic cancer: towards personalised medicine. Journal of Radiotherapy in Practice 2022; 21(3): 421 doi: 10.1017/S1460396921000182
|
| 52 |
Sheng Chen, Ye Wang, Wen-Long Zhang, Mao-Sheng Dong, Jian-Hua Zhang. Sclareolide enhances gemcitabine-induced cell death through mediating the NICD and Gli1 pathways in gemcitabine-resistant human pancreatic cancer. Molecular Medicine Reports 2017; 15(4): 1461 doi: 10.3892/mmr.2017.6182
|
| 53 |
Stefano Coppola, Ilaria Carnevale, Erik H.J. Danen, Godefridus J. Peters, Thomas Schmidt, Yehuda G. Assaraf, Elisa Giovannetti. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. Drug Resistance Updates 2017; 31: 43 doi: 10.1016/j.drup.2017.07.001
|
| 54 |
R. Nicolle, O. Gayet, M. Bigonnet, J. Roques, B. Chanez, F. Puleo, J. Augustin, J.F. Emile, M. Svrcek, T. Arsenijevic, P. Hammel, V. Rebours, M. Giovannini, P. Grandval, L. Dahan, V. Moutardier, E. Mitry, J.L. Van Laethem, J.B. Bachet, J. Cros, J. Iovanna, N.J. Dusetti. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer. Translational Oncology 2022; 16: 101315 doi: 10.1016/j.tranon.2021.101315
|
| 55 |
Praveen Bhoopathi, Padmanabhan Mannangatti, Swadesh K. Das, Paul B. Fisher, Luni Emdad. Pancreatic Cancer: Basic Mechanisms and Therapies. Advances in Cancer Research 2023; 159: 285 doi: 10.1016/bs.acr.2023.02.010
|
| 56 |
Carlos Urey, Bodil Andersson, Daniel Ansari, Agata Sasor, Katarzyna Said-Hilmersson, Johan Nilsson, Roland Andersson. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. Scandinavian Journal of Gastroenterology 2017; 52(5): 595 doi: 10.1080/00365521.2017.1290134
|
| 57 |
Mattia D. Pizzagalli, Ariel Bensimon, Giulio Superti‐Furga. A guide to plasma membrane solute carrier proteins. The FEBS Journal 2021; 288(9): 2784 doi: 10.1111/febs.15531
|
| 58 |
R. Nicolle, O. Gayet, P. Duconseil, C. Vanbrugghe, J. Roques, M. Bigonnet, Y. Blum, N. Elarouci, L. Armenoult, M. Ayadi, A. de Reyniès, F. Puleo, J. Augustin, J.F. Emile, M. Svrcek, T. Arsenijevic, P. Hammel, M. Giovannini, P. Grandval, L. Dahan, V. Moutardier, M. Gilabert, J.L. Van Laethem, J.B. Bachet, J. Cros, J. Iovanna, N.J. Dusetti. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Annals of Oncology 2021; 32(2): 250 doi: 10.1016/j.annonc.2020.10.601
|
| 59 |
Jiajia Li, Liyao Peng, Qun Chen, Ziping Ye, Tiantian Zhao, Sicong Hou, Jianguo Gu, Qinglei Hang. Integrin β1 in Pancreatic Cancer: Expressions, Functions, and Clinical Implications. Cancers 2022; 14(14): 3377 doi: 10.3390/cancers14143377
|
| 60 |
Anteneh Tesfaye, Philip A. Philip. Textbook of Gastrointestinal Oncology. 2019; : 255 doi: 10.1007/978-3-030-18890-0_15
|
| 61 |
Steven Alexander Mann, Romil Saxena. Predictive Biomarkers in Oncology. 2019; : 437 doi: 10.1007/978-3-319-95228-4_40
|